Trial Profile
Assessing Long-term Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions-LEA
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms LEA
- Sponsors AbbVie
- 14 Oct 2019 Status changed from recruiting to discontinued.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.
- 28 Nov 2017 Planned number of patients changed from 500 to 200.